LAKE FOREST, Calif., Feb. 20 /PRNewswire/ -- HemoCue, Inc. today announced that it has signed a distribution agreement with Cardinal Health. This is an important step for HemoCue, Inc. in expanding its distribution network in both the physician office and hospital markets. The products that Cardinal Health will carry include HemoCue’s data management, hemoglobin, glucose, and urine albumin systems.
HemoCue is committed to providing the best products in point-of-care testing. In hospital settings, the Hb 201 DM System is most suitable for ER and OR where fast and accurate hemoglobin results are critical. The Glucose 201 DM System provides superior precision and accuracy and is most suitable for critical care settings and Tight Glycemic Control programs.
This distribution expansion will further strengthen HemoCue, Inc.'s penetration in the U.S. professional healthcare market, adding to the existing partnership with leading U.S. distributors.
About HemoCue, Inc.
HemoCue is a leader in the development, manufacturing, and marketing of advanced medical testing systems that bring lab-quality results to the point-of-care. Its leading products include hemoglobin, glucose, and urine albumin point-of-care testing systems. The fundamental concept behind HemoCue products is the ability to perform common blood and urine tests at the point-of-care without sacrificing the accuracy and precision offered by a central clinical lab.
HemoCue is owned by EQT, a leading private equity group in Northern Europe.
For additional information about HemoCue, or its products and services, visit http://www.hemocue.com.
HemoCue, Inc.
CONTACT: Lily Sunkin, National Marketing Manager of HemoCue, Inc.,+1-800-881-1611, lily@hemocue.com
Web site: http://www.hemocue.com/
